Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Safety and Effectiveness Study of SQ-Kyrin System for Functional Mitral Regurgitation in EU

A legfontosabb adatok

Ki végzi
Shanghai Shenqi Medical Technology Co., Ltd
Hol
Spanyolország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
34 fő, tervezett
Kezdés
2024. dec. 17.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • SQ-Kyrin Transcatheter Mitral Valve Repair System
A regiszteradat frissítve
2025. február 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 43 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant who has provided written informed consent for the investigation
  • Age ≥18 years
  • Patients diagnosed with FMR
  • MR severity is (functional) ≥3+ as determined by transthoracic echocardiography (TTE)
  • LVEF ≥20% to ≤60%
  • Symptom status: NYHA functional class II to IV despite a stable maximally tolerated GDMT regimen as per guidelines
  • According to the judgment of local cardiology team, subjects have undergone adequate treatment for at least 30 days (preferably 90 days) based on the criteria recommended in the heart failure guidelines
  • Subject fulfils FMR anatomy selection criteria
  • According to the judgment of the local Cardiovascular medical-surgery team, subjects who have high or prohibitive risk for open heart surgery
  • Left ventricular end-systolic diameter (LVESD)≤70mm
  • The MR beam mainly originates from the A2/P2 area
  • Mitral valve coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets>10mm
  • Mitral valve effective orifice area (EOA) ≥ 4.0cm2
  • No obvious calcification of main grasp mitral valve leaflets
  • Patient anatomy allows atrial septum approach

Ki nem vehet részt

  • UNOS status 1 heart transplantation or prior orthotopic heart transplantation
  • Mitral valve area < 4.0 cm2 (if new device therapy may further decrease the mitral orifice area)
  • Any prior mitral valve surgery or transcatheter mitral valve procedure
  • Stroke or transient ischemic event within 30 days before enrolment
  • Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 1 month before enrolment
  • Aortic valve disease requiring intervention or any concomitant treatment
  • Life expectancy <1 year due to non-cardiac conditions or heart failure deemed suitable for palliative treatment
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
  • Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction
  • Need for emergent or urgent intervention for any reason or any planned cardiac intervention within the next 12 months
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Tricuspid valve disease requiring intervention or severe or more tricuspid regurgitation
  • Need for any cardiovascular intervention (other than for MV disease)
  • Active infections requiring current antibiotic therapy
  • Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits
  • Patients with severe liver, renal or pulmonary disease, which in investigator opinion may have an impact on patient safety
  • Hypotension (systolic pressure <90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support
  • Fixed pulmonary artery systolic pressure >70 mm Hg
  • Mitral valve anatomy which may preclude proper device treatment
  • Modified Rankin ≥ Scale 4 disability
  • Severe symptomatic carotid stenosis (>70% by ultrasound)
  • Any percutaneous cardiovascular intervention, cardiovascular intervention, or carotid intervention within 30 days
  • Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
  • Active endocarditis
  • Subjects in whom transoesophageal echocardiography is contraindicated or high risk
  • Patient unable or unwilling to provide written, informed consent before study enrolment
  • Pregnant woman or woman planning to become pregnant
  • Clinically significant lab abnormalities which in investigator opinion may have an impact on patient safety

Ez a vizsgálat jelenleg itt érhető el: Spanyolország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The investigation objective of this study is to evaluate the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in the population of FMR patients and the accessories devices when used in conjunction with the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter.

A vizsgálat csoportja

  • SQ-Kyrin TMVr SystemA vizsgált kezelés

    Kezelés: SQ-Kyrin Transcatheter Mitral Valve Repair System

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multicenter, Single Arm Study to Evaluate the Safety and Effectiveness of Shenqi Transcatheter Mitral Valve Clips Delivery System and Steerable Guide Catheters in Patients with Functional Mitral Regurgitation
A regiszteradat frissítve
2025. február 12.